$ELEV News
Last published 1y ago
- 1y agoELEVElevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value RightPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 1y agoELEVElevation Oncology Reports First Quarter 2025 Financial Results and Provides Business UpdatesPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 1y agoELEVElevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025PR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 1y agoELEVElevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025PR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 1y agoELEVElevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic OptionsPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 1y agoELEVElevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business AchievementsPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 1y agoELEVElevation Oncology to Participate in Upcoming Investor ConferencesPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 1y agoONCYADPTNEOELEV+2Cutting-Edge Cancer Therapies Lead the Way into a Transformative YearPR NewswireAs 2025 begins, the American Association for Cancer Research (AACR) recently published forecasts from experts showcasing transformative advances in...
- 1y agoELEVElevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming MilestonesPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 1y agoELEVElevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid TumorsPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 1y agoELEVElevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024PR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 1y agoELEVElevation Oncology to Present at the Piper Sandler 36th Annual Healthcare ConferencePR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business AchievementsPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2PR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment ConferencePR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business AchievementsPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2PR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction CancerPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology to Present at the Citizens JMP Life Sciences ConferencePR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business AchievementsPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024PR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business AchievementsPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024PR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of DirectorsPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology to Participate in Upcoming Investor ConferencesPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in JapanPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of DirectorsPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoAMAMAMGNELEVNKTX+1Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030GlobeNewswirePALM BEACH, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to the report titled "Aging in the United States," published by the Population Reference Bureau, "the number of
- 2y agoELEVElevation Oncology Announces Program Updates and Upcoming 2024 MilestonesPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 2y agoELEVElevation Oncology to Present at the Piper Sandler 35th Annual Healthcare ConferencePR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 3y agoELEVElevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business AchievementsPR NewswireElevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to...
- 3y agoELEVElevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment ConferencePR NewswireNEW YORK, Sept. 5, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of
- 3y agoELEVElevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021PR NewswireNEW YORK, Aug. 16, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of
- 3y agoELEVElevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business AchievementsPR NewswireInitial Phase 1 SYSA1801 (EO-3021) data presented by partner CSPC Pharmaceutical Group Limited at ASCO 2023 showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer
- 3y agoELEVElevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial OfficerPR NewswireNEW YORK, July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of
- 3y agoELEVElevation Oncology Announces Pricing of $50 Million Public OfferingPR NewswireNEW YORK, June 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of
- 3y agoELEVElevation Oncology Announces Launch of Proposed Public OfferingPR NewswireNEW YORK, June 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of
- 3y agoCSPCYELEVElevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023PR NewswireInitial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Elevation Oncology on track to
- 3y agoELEVElevation Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Business AchievementsPR NewswirePartner CSPC Pharmaceutical Group Limited's ongoing Phase 1 SYSA1801 (EO-3021) clinical trial data selected for poster presentation and poster discussion at ASCO 2023Presented EO-3021 preclinical proof-of-concept
- 3y agoCSPCYELEVElevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023PR NewswireNEW YORK, April 26, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of
- 3y agoELEVElevation Oncology Presents EO-3021 Preclinical Proof-of-Concept Data and Highlights a Clinical Case Study in Claudin 18.2-Expressing Cancers at AACR 2023PR NewswireEO-3021 demonstrated anti-tumor activity in preclinical models expressing varying levels of Claudin 18.2 EO-3021 induced a confirmed partial response in a patient with metastatic gastric cancer Company is on track to
- 3y agoELEVElevation Oncology to Present at the American Association of Cancer Research (AACR) Annual Meeting 2023PR Newswire- Company plans to highlight preclinical proof-of-concept data for EO-3021 in an oral presentation at the New Drugs on the Horizon special session NEW YORK, March 14, 2023 /PRNewswire/ -- Elevation Oncology, Inc.
- 3y agoELEVElevation Oncology Reports Fourth Quarter and Full Year 2022 Financial ResultsPR NewswireRemain on track to present EO-3021 preclinical proof-of-concept data in first half of 2023, and initiate Phase 1 clinical trial in the US in second half of 2023Announced pipeline prioritization and realignment of
- 3y agoELEVElevation Oncology to Participate at Upcoming Investor ConferencesPR NewswireNEW YORK, March 1, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of
- 3y agoELEVElevation Oncology to Present at the SVB Securities Global Biopharma ConferencePR NewswireNEW YORK, Feb. 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of
- 3y agoELEVElevation Oncology to Present at the 41st Annual J.P. Morgan Healthcare ConferencePR NewswireNEW YORK, Jan. 9, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of
- 3y agoELEVElevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO TransitionPR NewswirePrioritizing the development of EO-3021, a potential best-in-class ADC targeting Claudin18.2, and additional pipeline programs including those through its existing partnership with Caris Life SciencesPlanning to present
- 3y agoELEVElevation Oncology to Participate at the JMP Securities Hematology and Oncology SummitPR NewswireNEW YORK, Nov. 30, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers,
- 4y agoELEVElevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company ProgressPR NewswireOn track to report additional interim seribantumab data from the Phase 2 CRESTONE study in the first half of 2023Preparations are underway to initiate a Phase 1 clinical trial of EO-3021 in the US in 2023NEW YORK, Nov.
- 4y agoELEVElevation Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company ProgressPR NewswirePresented initial seribantumab proof-of-concept data from Phase 2 CRESTONE study at ASCO 2022, including 33% response rate with two complete responses across all tumor types harboring NRG1 fusions Seribantumab granted Fast Track designation by FDA for